AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich Ataxia

Дата публикации: 01-08-2026 00:00:00

This nonrandomized clinical trial evaluates the safety and preliminary efficacy of administration of AAVrh.10hFXN to adults as gene therapy to treat Friedreich ataxia cardiomyopathy.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Change to Open Access Status	0	12.96	01-08-2026
2	Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease	0	8.74	28-07-2026
3	Exercise Performance With Aficamten vs Metoprolol in oHCM	0	6.05	01-08-2026
4	Fecal Microbiota Transplantation for Treatment of Parkinson Disease	0	4.44	01-09-2024
5	Gefurulimab and Generalized Myasthenia Gravis	0	10.42	27-07-2026
6	RAFT-OS Transplant for Aniridia-Related Keratopathy	0	19.17	23-07-2026
7	Teriflunomide and Time to Clinical Multiple Sclerosis in Radiologically Isolated Syndrome	0	6.92	01-10-2023
8	Erythropoietin for Neonatal Hypoxic-Ischemic Encephalopathy	0	13.05	27-07-2026
9	Ultralow-Dose IL 10–Expressing CAR T Cells in Relapsed/Refractory Diffuse Large B-Cell Lymphoma	0	14.62	23-07-2026
10	Разработана генная терапия от детской кардиомиопатии	0	13.31	19-08-2026

Классификация: Наука. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 9.08. Источник: archderm.jamanetwork.com.